Jaguar Health, Inc. (NASDAQ:JAGX) was the target of a surge in short interest during December. As of December 31, there was short interest totaling 3,490,000 shares, an increase of 40.2% from the total of 2,490,000 shares as of December 15. Approximately 8.5% of the company’s shares are sold short. Based on an average daily trading volume of 3,340,000 shares, the day-to-cover ratio is currently 1.0 day.

Institutional investors have recently increased or reduced their stake in the company. Jump Financial LLC bought a new position in Jaguar Health during Q3 for a value of approximately $67,000. Morgan Stanley bought a new position in Jaguar Health during Q1 for a value of around $159,000. Northern Trust Corp increased its position in Jaguar Health shares by 4.4% during the second quarter. Northern Trust Corp now owns 230,797 shares of the biotech company worth $365,000 after buying 9,653 additional shares during the period. State Street Corp acquired a new stake in shares of Jaguar Health during Q2 for a value of approximately $625,000. Finally, Geode Capital Management LLC increased its position in Jaguar Health shares by 25.3% during the second quarter. Geode Capital Management LLC now owns 1,088,159 shares of the biotech company worth $1,719,000 after purchasing an additional 219,492 shares during the period. Hedge funds and other institutional investors own 15.95% of the company’s shares.

A number of research analysts have recently released JAGX stock reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $5.00 price target on Jaguar Health shares in a Monday, September 20 report. Zacks Investment Research downgraded Jaguar Health shares from a “buy” rating to a “hold” rating in a report on Tuesday, November 23.

Jaguar Health stock traded down $0.01 at midday on Monday, hitting $0.96. 1,081,228 shares were traded, against an average volume of 2,681,150. The company has a quick ratio of 1.63, a current ratio of 2.01 and a leverage ratio of 1.16. Jaguar Health has a 12 month minimum of $0.88 and a 12 month maximum of $10.89. The company’s fifty-day simple moving average is $1.29 and its two-hundred-day simple moving average is $2.52.

Jaguar Health Inc (NASDAQ:JAGX) last released its quarterly results on Wednesday, November 17. The biotech company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.09). Jaguar Health had a negative return on equity of 183.74% and a negative net margin of 973.74%. The company had revenue of $0.63 million for the quarter. During the same period last year, the company posted ($0.63) EPS. Equity analysts predict that Jaguar Health will post an EPS of -0.73 for the current year.

About Jaguar Health

Jaguar Health, Inc is a commercial-stage pharmaceutical company, which is engaged in the development of gastrointestinal products. The Company is focused on developing new herbal, non-opioid and sustainably derived prescription medicines for people and animals suffering from gastrointestinal distress, particularly chronic and debilitating diarrhea.

Feature Article: CBOE Russell 2000® Volatility Index

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Jaguar Health right now?

Before you consider Jaguar Health, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Jaguar Health wasn’t on the list.

Although Jaguar Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here